Table 1.
Baseline characteristics of the study population
| Total (n=1,944) | Before 2008 (n=456) | 2008 to 2012 (n=859) | After 2013 (n=629) | P-value | |
|---|---|---|---|---|---|
| Age (years) | 48 (37–57) | 47 (35–57) | 46 (37–54) | 51 (41–60) | <0.001 |
| Males | 1,135 (58.4) | 336 (73.7) | 481 (56.0) | 318 (50.5) | <0.001 |
| Laboratory findings | |||||
| Hemoglobin (g/dL) | 13.05±1.97 | 13.26±2.02 | 13.19±1.88 | 12.7±2.02 | <0.001 |
| Platelets (103/µL) | 202.5±85.74 | 193.78±85.23 | 201.56±87.13 | 210.1±83.64 | 0.007 |
| Total bilirubin (mg/dL) | 0.82 (0.59–1.26) | 0.78 (0.55–1.19) | 0.85 (0.62–1.27) | 0.82 (0.6–1.31) | 0.011 |
| Albumin (g/dL) | 3.92±0.56 | 3.93±0.53 | 4.01±0.54 | 3.79±0.58 | <0.001 |
| AST (U/L) | 51 (31–94) | 52 (31–98) | 48 (30–91) | 52 (32–95) | 0.195 |
| ALT (U/L) | 48 (24–110) | 45 (25–93.5) | 47 (24–108.5) | 50 (24–118.75) | 0.701 |
| Creatinine (mg/dL) | 1.02±0.97 | 1.05±0.83 | 1.00±0.89 | 1.02±1.15 | 0.576 |
| PT (INR) | 1.08±0.16 | 1.09±0.14 | 1.08±0.19 | 1.09±0.15 | 0.560 |
| Liver cirrhosis | 563 (28.96) | 141 (30.92) | 244 (28.41) | 178 (28.30) | 0.567 |
| Medication | |||||
| Antiplatelet | 56 (2.88) | 9 (1.97) | 32 (3.73) | 15 (2.38) | 0.129 |
| Warfarin | 2 (0.10) | 1 (0.22) | 0 (0.00) | 1 (0.16) | 0.432 |
| NSAID | 73 (3.76) | 16 (3.51) | 35 (4.07) | 22 (3.50) | 0.803 |
Values are presented as mean±standard deviation, median (range) for continuous variables, or frequency (percentage) for categorical variables. The proportions are presented as percentages for categorical variables.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalized ratio; NSAID, non-steroidal antiinflammatory drugs.